Abstract
Evidence is accumulating that aberrant microRNA(miRNA)expression contributes to the development and metastasis of cancer. Emerging evidence demonstrates that miRNA plays an important role in drug resistance in ovarian cancer and that it may become a new therapeutic target. It is important to further elucidate the mechanisms of miRNA associated drug resistance in ovarian cancer. Key words: MicroRNA; Ovarian neoplasms; Drug resistance; Cisplatin
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
